Newsmeme!
Discover News you didn't know existed
Smoke billows from Mullan Tunnel long after the westbound train begins its tedious descent off the Continental Divide.
XenoPort, Inc. (Nasdaq:XNPT) announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
The Seasonal Gold Chart above displays gold price movement in several ways. First, the red arrow shows where we’re at now. Next, the blue line is made up of the past 15-years of data to calculate a current average of prices.
SANTA CLARA, Calif.----XenoPort, Inc. announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil , also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury .
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |